POLQ identifies a better response subset to immunotherapy in muscle‐invasive bladder cancer with high PD‐L1

POLQ identifies a better response subset to immunotherapy in muscle‐invasive bladder cancer with high PD‐L1

Abstract Background Though programmed cell death‐ligand 1 (PD‐L1) has been used in predicting the efficacy of immune checkpoint blockade (ICB), it is insufficient as a single biomarker. As a key effector of an intrinsically mutagenic microhomology‐mediated end joining (MMEJ) pathway, DNA polymerase...

Full description

Bibliographic Details
Main Authors: Ge Liu, Kaifeng Jin, Zhaopei Liu, Xiaohe Su, Ziyue Xu, Bingyu Li, Jingtong Xu, Yuan Chang, Yiwei Wang, Yu Zhu, Le Xu, Jiejie Xu, Zewei Wang, Hailong Liu, Weijuan Zhang
Format: Article
Language:English
Published: Wiley 2024-02-01
Series:Cancer Medicine
Subjects:
immunotherapy
muscle‐invasive bladder cancer
PD‐L1
platinum‐based chemotherapy
POLQ
Online Access:https://doi.org/10.1002/cam4.6962

Similar Items

Similar Items